GlassScriptPhysician profile
Michelle Zebrowski
NPI 1679847651
$7,089.14
in general payments reported to CMS, 2019-2025
24 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $846 · 2022: $1,003 · 2023: $1,259 · 2024: $2,188 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,228 · Education: $12.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,227.71 |
| Education | $12.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,451.80 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $703.54 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $683.72 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $543.39 | 2021-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $370.53 | 2024-2025 | Voquezna |
| Genzyme Corporation | $267.52 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $265.18 | 2021-2025 | Linzess |
| Ardelyx, INC. | $249.02 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $199.02 | 2021-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $191.80 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $151.29 | 2021-2025 | Epclusa |
| Lilly USA, LLC | $134.31 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $129.00 | 2023 | Zeposia |
| Vifor Pharma, INC. | $118.76 | 2022 | |
| Axonics, INC. | $109.03 | 2022-2024 | Axonics |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $107.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $82.36 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $74.67 | 2024-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $67.49 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $65.27 | 2025 | Zenpep |
| Pfizer INC. | $45.29 | 2023-2024 | |
| Redhill Biopharma INC. | $36.55 | 2021-2024 | Talicia |
| Nestle Healthcare Nutrition INC. | $24.10 | 2021 | |
| Vivus LLC | $17.76 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Zebrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.